Drug-Induced Anaemias

Rh, Girdwood

doi:10.2165/00003495-197611050-00003

Cited by 23 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mild effects on hemoglobin were evident, but no appreciable Reversible myelosuppression is manageable and common with antibiotics (4,10,12). Current recommendations suggest monitoring of complete blood counts in predisposed patients (Zyvox package insert, Pharmacia & Upjohn Company; Peterson, letter).…”

mentioning

confidence: 99%

Hematologic Effects of Linezolid: Summary of Clinical Experience

Gerson

Kaplan

Bruss³

et al. 2002

Antimicrob Agents Chemother

399

231

View full text Add to dashboard Cite

Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at >2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.

show abstract

mentioning

confidence: 99%

Hematologic Effects of Linezolid: Summary of Clinical Experience

Gerson

Kaplan

Bruss³

et al. 2002

Antimicrob Agents Chemother

399

231

View full text Add to dashboard Cite

show abstract

“…These possible causes include interference with folate or vitamin B12 absorption, plasma transport, or delivery, competition for reductases, etc [ 12 ]. Many antineoplastic drugs can cause megaloblastic anemia, such as thioguanine, gemcitabine and pemetrexed, etc [ 13 ]. However, megaloblastic anemia caused by EGFR TKIs are very rare.…”

Section: Discussionmentioning

confidence: 99%

Severe megaloblastic anemia in a patient with advanced lung adenocarcinoma during treatment with erlotinib: a case report and literature review

Yan,

Kong,

Wang

et al. 2024

BMC Pulm Med

View full text Add to dashboard Cite

Background Erlotinib is a first-generation, tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) used for the treatment patients with NSCLC. Erlotinib is considered as a safe and effective treatment option, with generally good tolerance. Diarrhea and rash are the most common side effects, and more rare side effects appear in long-term real-world applications. Severe erlotinib related megaloblastic anemia is rare and remains unreported. This is the first case report of severe megaloblastic anemia in a patient with advanced lung adenocarcinoma with an EGFR L858R mutation treated with erlotinib. In this report, the clinical manifestations, diagnosis and treatment of erlotinib related severe megaloblastic anemia are described, and the possible pathogenesis and related treatment options are discussed. Case description Herein, we present a 57- year-old non-smoking female diagnosed with metastatic lung adenocarcinoma harboring an EGFR L858R mutation, who had received erlotinib as the first-line therapy. After 44 weeks of treatment, the patient developed severe anemia. Anemia was manifested as megaloblastic anemia with elevated mean corpuscular volume and mean corpuscular hemoglobin. The total vitamin B12 level was below the detection limit of 50.00 pg /mL. Bone marrow smear suggested megaloblastic anemia. Her hematologic parameters were markedly recovered following the withdrawal of erlotinib and vitamin B12 supplement. As a result, the patient was diagnosed with erlotinib-associated megaloblastic anemia. Conclusions This is the first case of severe megaloblastic anemia reported with erlotinib. Few of these hematologic adverse effects have been observed in studies on erlotinib, this case report highlights this possibility for long-term erlotinib administration. Close clinical and blood monitoring is recommended for patients receiving long-term TKI therapy.

show abstract

“…49 Bone marrow suppression is a common adverse reaction of chemotherapeutics, with bone marrow aplasia often being lifethreatening. 50,51 We are the first to report this adverse reaction in sacituzumab govitecan. Currently, there is no well-established treatment plan for acquired aplastic anemia.…”

Section: Articlementioning

confidence: 95%

Postmarketing Safety of Sacituzumab Govitecan: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System

Li,

Zhang,

et al. 2023

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Sacituzumab govitecan is widely used for the treatment of breast cancer and urothelial carcinoma, but available information regarding adverse events (AEs) is limited. We aim to explore the AE induced by sacituzumab govitecan by mining the FDA Adverse Event Reporting System (FAERS) database. The association between sacituzumab govitecan and AEs was evaluated using the information component. A multivariate logistic regression analysis was conducted for all identified signals to explore the risk factors associated with AEs leading to hospitalization. In total, 1,884 reports related to sacituzumab govitecan were retrieved, and 114 AE signals involving 20 systems were identified. The median time for onset of AEs was ~ 6–7 days after initiating treatment with sacituzumab govitecan, with over 80% of AEs occurring within 30 days. Subgroup analysis revealed that 14 signals were reported in men and 110 in women. There were 58 signals reported in patients under 65 following the use of sacituzumab govitecan, 59 signals in patients over 65, and 31 signals were present in both groups. Multivariable analysis showed that being male and the occurrence of colitis, pneumonitis, febrile neutropenia, pyrexia, sepsis, dehydration, and diarrhea were risk factors leading to hospitalization with an area under the curve (AUC) of 0.89. Additionally, sensitivity analysis revealed that this study had good robustness. This is the first retrospective analysis based on FAERS to review the safety of sacituzumab govitecan. The results highlight the need to closely monitor adverse reactions such as neutropenia, diarrhea, colitis, and sepsis when using sacituzumab govitecan.

show abstract

Drug-Induced Anaemias

Cited by 23 publications

References 42 publications

Hematologic Effects of Linezolid: Summary of Clinical Experience

Hematologic Effects of Linezolid: Summary of Clinical Experience

Severe megaloblastic anemia in a patient with advanced lung adenocarcinoma during treatment with erlotinib: a case report and literature review

Postmarketing Safety of Sacituzumab Govitecan: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System

Contact Info

Product

Resources

About